Showing 8261-8270 of 10720 results for "".
James Del Rosso, DO: Thoughts on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/james-del-rosso-do-thoughts-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24173/James Q. Del Rosso, DO, a dermatologist and president of The American Acne and Rosacea Society (AARS), weighs in on a recent report from Valisure which finds that benzene can form at elevated levels in products for acne that contain benzoyl peroxide (BPO). The interview was conducted by Neal Bhatia,Is it time to consider telemedicine at your dermatology practice?
https://practicaldermatology.com/topics/practice-management/is-it-time-to-consider-telemedicine-at-your-dermatology-practice/19779/Telemedicine is in high demand, now more than ever. This Ekwa Marketing video explores how well it fits with dermatology practices, and what it takes to implement it.Pigmentation Disorders
https://practicaldermatology.com/topics/pigmentary-disorders/pigmentation-disorders/19730/Sunscreen may be the first, second, and third thing recommended for patients with pigmentation disorders, but what comes next? Joel Cohen, MD interviews Amit Pandya, MD to learn about treatment options and developments in the pipeline.Atopic Dermatitis: Understanding the Impact
https://practicaldermatology.com/topics/atopic-dermatitis/atopic-dermatitis-understanding-the-impact/19667/For most AD patients, eczema is a bumpy ride. Even mild cases of atopic dermatitis can have a significant effect on people—and these effects range from quality of life impact to treatment costs. Peter Lio, MD describes his approach to a long-term eczema management plan.Cosmetic Boot Camp 2018 Presenter Insight
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/cosmetic-boot-camp-2018-presenter-insight/18290/Get up to date on Cosmetic Bootcamp. Presenters provide updates on microneedling, radiofrequency devices, lasers, fillers, neurotoxins, and more. The Cosmetic Bootcamp® provides training and educational opportunities for aesthetic medicine physicians and their staff. Hear from: Mary Lupo, MD; Vic NaEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andTalking to Patients: Men v. Women
https://practicaldermatology.com/topics/practice-management/talking-to-patients-men-v-women/18693/Every patient is unique, but aesthetic physicians may need to tailor their communication style based on the patient's sex. It's also essential to convey to men that you understand the male aesthetic and how their treatment goals may differ from the typical woman's.Tips on Expanding Your Practice Focus to Men
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/tips-on-expanding-your-practice-focus-to-men/18699/“I see the male patient as a huge opportunity I think men have been largely overlooked,” says Terrence Keaney, MD. He explains what procedures and services appeal to men, talks about the fundamentals of building a male-friendly practice, and offers tips to make male patients more comfortable undergoAubio Launches, Updates from Prescriber's Choice, BioPharmX
https://practicaldermatology.com/topics/practice-management/dermwiretv-aubio-launches-updates-from-prescriber-s-choice-biopharmx/18584/In this edition of DermWireTV, Aubio launches OTC treatment for cold sores with backing from Paul Mitchell partner. Prescriber's Choice facilitates in-office prescription dispensing. BioPharmX enrolls phase 2b trial for topical minocycline and Merz acquires ONLight Sciences, maker of PFD patch for tTarget: PASI 90
https://practicaldermatology.com/topics/psoriasis/target-pasi-90/18593/With new advancements in biologic therapy, patients are gaining more control of psoriasis. Whereas PASI 50 was once seen as a significant improvement, patients today can expect to achieve PASI 90. Can PASI 100 be far behind?